Key Takeaways
- The UK’s National Institute for Health and Care Excellence (NICE) now recommends routine NHS funding for ex‑situ machine perfusion devices, specifically highlighting Bridge to Life’s VitaSmart™ Hypothermic Oxygenated Perfusion (HOPE) System.
- NICE’s guidance (HTG780, published August 20, 2026) concludes that hypothermic oxygenated perfusion improves graft survival and reduces biliary complications compared with traditional static cold storage, delivering both clinical and financial advantages.
- Bridge to Life’s CEO, Don Webber, calls the NICE endorsement a milestone that establishes HOPE as the emerging standard of care for liver transplantation in Europe and supports U.S. adoption following FDA De Novo clearance.
- VitaSmart™ is designed for operational simplicity, ease of integration into existing workflows, and capital efficiency, avoiding the complexity and high costs of normothermic perfusion systems.
- The system is already commercially available in the United States, United Kingdom, Europe, Saudi Arabia, India, and all CE‑mark‑accepting countries, reflecting broad international adoption.
- Clinician Rebeca Sanabria Mateos notes that equitable access to VitaSmart enables safer use of extended‑criteria donor organs, streamlines OR logistics, and improves patient outcomes.
- Bridge to Life positions VitaSmart alongside its Belzer UW® cold‑static preservation franchise, offering a differentiated portfolio that spans established and next‑generation organ preservation technologies.
NICE Endorses Routine Funding for Machine Perfusion Devices
On August 27, 2026, Bridge to Life™ Ltd. announced that the United Kingdom’s National Institute for Health and Care Excellence (NICE) has issued new HealthTech guidance recommending routine National Health Service (NHS) funding for ex‑situ machine perfusion devices used to preserve deceased donor livers. The guidance specifically cites Bridge to Life’s VitaSmart™ Hypothermic Oxygenated Perfusion (HOPE) System as an example of the technology now eligible for standard NHS reimbursement. This endorsement follows a thorough evaluation of clinical and economic evidence, positioning machine perfusion as a reimbursable standard of care within the UK’s transplant ecosystem.
Clinical Evidence Supporting Hypothermic Oxygenated Perfusion
NICE’s full guidance (Reference number: HTG780, published August 20, 2026) details the results of a rigorous assessment comparing machine perfusion to traditional static cold storage. The analysis found that hypothermic oxygenated perfusion confers clear clinical benefits, including higher graft survival rates and a notable reduction in biliary complications post‑transplant. These outcomes address two persistent challenges in liver transplantation: early graft dysfunction and ischemic cholangiopathy, both of which can compromise long‑term patient health and increase healthcare costs.
Economic Advantages Highlighted by NICE
Beyond clinical improvements, NICE concluded that advanced perfusion systems deliver financial value to the NHS. By reducing the incidence of graft failure and biliary complications, HOPE lowers the need for costly re‑transplants, prolonged intensive care stays, and additional interventions. The guidance emphasizes that the upfront investment in perfusion technology is offset by downstream savings, making it a cost‑effective strategy for expanding the donor pool while maintaining or improving overall budgetary impact.
Leadership Perspective from Bridge to Life
Don Webber, CEO and President of Bridge to Life™ Ltd., described the NICE recommendation as a milestone that propels hypothermic oxygenated perfusion toward becoming the standard of care in liver transplantation. He noted that Europe has utilized HOPE for over a decade, demonstrating its reliability and value across diverse clinical settings. Webber added that the NICE validation provides further confidence in HOPE’s clinical and economic advantages, especially as U.S. physicians begin to adopt the technology following the device’s FDA De Novo clearance. He emphasized that VitaSmart™ was engineered to deliver these proven benefits in a format that is simple, scalable, and cost‑efficient for hospitals worldwide.
Features and Design Philosophy of VitaSmart™
The VitaSmart™ Hypothermic Oxygenated Perfusion System operationalizes HOPE by circulating an oxygenated preservation solution through donor livers at hypothermic temperatures prior to implantation. Bridge to Life designed the platform for operational simplicity, enabling seamless integration into existing transplant workflows without the steep learning curve or extensive infrastructure changes often associated with normothermic perfusion systems. VitaSmart™ avoids the heavy capital expenditure and complex consumable requirements of normothermic devices, instead offering a streamlined, user‑friendly solution that can be adopted quickly by transplant centers seeking to enhance organ quality while controlling costs.
Global Availability and Expanding Adoption
VitaSmart™ is already commercially available in multiple regions, including the United States, United Kingdom, across Europe, Saudi Arabia, India, and in all countries that accept the CE mark. Bridge to Life highlights that the system’s broad international presence reflects both proven efficacy and market confidence. In the U.S., the recent FDA De Novo clearance has accelerated commercial growth, allowing more transplant programs to access HOPE technology. Simultaneously, longstanding European adoption continues to generate real‑world data reinforcing the system’s benefits, creating a feedback loop that supports continual refinement and wider uptake.
Clinical Impact According to Transplant Surgeons
Rebeca Sanabria Mateos, Consultant Liver Transplant Surgeon at University Hospitals Birmingham NHS Foundation Trust, praised the NHS funding decision as heralding a new era for liver transplantation programs in the UK. She stressed that equitable access to efficient, user‑friendly perfusion technology empowers surgical teams to safely employ extended‑criteria donor organs, thereby increasing the pool of usable grafts. Mateos also noted that VitaSmart™ streamlines operating‑room logistics, reduces ischemia‑related complications, and ultimately leads to better patient outcomes—aligning with the broader goals of modern transplant medicine to maximize donor utilization while safeguarding recipient health.
Strategic Positioning Within Bridge to Life’s Portfolio
Bridge to Life situates VitaSmart™ alongside its established Belzer UW® cold‑static preservation solution, which remains the global gold standard for organ flushing and is the most widely used cold preservative in abdominal organ transplantation. Together, these products give the company a differentiated market position that spans both proven, legacy preservation methods and next‑generation machine perfusion technologies. This dual‑focus strategy enables Bridge to Life to serve a broad spectrum of transplant centers—from those seeking reliable, low‑cost static storage to early adopters pursuing advanced perfusion to enhance organ viability and expand the donor pool.
Conclusion and Outlook
The NICE endorsement of routine NHS funding for ex‑situ machine perfusion devices marks a pivotal moment for liver transplantation in the United Kingdom and signals a growing acceptance of HOPE as a standard clinical practice. Bridge to Life’s VitaSmart™ system, with its emphasis on simplicity, cost‑efficiency, and proven clinical benefits, is well positioned to meet this rising demand. As more health systems recognize the value of hypothermic oxygenated perfusion—both in terms of improved graft survival and reduced long‑term healthcare expenditures—adoption is likely to accelerate across Europe, North America, and emerging markets. Continued investment in evidence‑based preservation science, coupled with strategic global expansion, will enable Bridge to Life to further its mission of expanding the donor pool, streamlining transplant workflows, and ultimately improving patient outcomes worldwide.